Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients
Open Access
- 13 June 2015
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (26) , 22227-22238
Abstract
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Xia-Ying Kuang1, 2, *, Li Chen1, 2, *, Zhi-Jie Zhang4, Yi-Rong Liu1, 2, Yi-Zi Zheng1, 2, Hong Ling2, Feng Qiao2, Shan Li2, Xin Hu2, Zhi-Ming Shao1, 2, 3 1Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China 3Institutes of Biomedical Science, Fudan University, Shanghai, China 4Department of Epidemiology and Biostatistics, School of Public Health, Fudan University, Shanghai, China *These authors have contributed equally to this work Correspondence to: Zhi-Ming Shao, e-mail: zhimingshao@yahoo.com Xin Hu, e-mail: xinhu@fudan.edu.cn Keywords: stathmin, phosphorylation, breast cancer, prognostic model, paclitaxel Received: March 11, 2015 Accepted: June 01, 2015 Published: June 13, 2015 ABSTRACT Currently, Stathmin1 (STMN1) and phospho-STMN1 levels in breast cancers and their clinical implications are unknown. We examined the expression of STMN1 and its serine phospho-site (Ser16, Ser25, Ser38, and Ser63) status by immunohistochemistry. Using Cox regression analysis, a STMN1 expression signature and phosphorylation profile plus clinicopathological characteristics (STMN1-E/P/C) was developed in the training set (n = 204) and applied to the validation set (n = 106). This tool enabled us to separate breast cancer patients into high- and low-risk groups with significantly different disease-free survival (DFS) rates (P < 0.001). Importantly, this STMN1-E/P/C model had a greater prognostic value than the traditional TNM classifier, especially in luminal subtype breast cancer (P = 0.002). Further analysis showed that patients in the low-risk group would benefit more from adjuvant paclitaxel-based chemotherapy (P = 0.002). In conclusion, the STMN1-E/P/C signature is a reliable prognostic indicator for luminal subtype breast cancer and may predict the therapeutic response to paclitaxel-based treatments, potentially facilitating individualized management.Keywords
This publication has 34 references indexed in Scilit:
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology, 2013
- Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without PaclitaxelPLOS ONE, 2012
- Siva1 suppresses epithelial–mesenchymal transition and metastasis of tumor cells by inhibiting stathmin and stabilizing microtubulesProceedings of the National Academy of Sciences, 2011
- Regulation of Microtubule Dynamics through Phosphorylation on Stathmin by Epstein-Barr Virus Kinase BGLF4Journal of Biological Chemistry, 2010
- Regulation of Microtubule Dynamic Instability in Vitro by Differentially Phosphorylated StathminJournal of Biological Chemistry, 2009
- Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activationProceedings of the National Academy of Sciences, 2009
- Stathmin Activity Influences Sarcoma Cell Shape, Motility, and Metastatic PotentialMolecular Biology of the Cell, 2008
- Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activityProceedings of the National Academy of Sciences, 2007
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998